$MPSYF News
Last published 4y ago
- 4y agoMORMPSYFMorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022ACCESS NewswireConference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:00
- 4y agoMORMPSYFMorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022ACCESS NewswirePreliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million) Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million) Update of R&D expense guidance (now € 275 to € 300
- 4y agoMORMPSYFMorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022ACCESS NewswirePublication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million) Update of financial guidance ranges for 2022 Monjuvi U.S
- 4y agoMORMPSYFMorphoSys AG Reports Outcome of Annual General Meeting 2022ACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual Genera
- 4y agoMORMPSYFInvitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022ACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT). MorphoSys' Management team will host a conference
- 4y agoMORMPSYFMorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCLACCESS NewswireMorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Minjuvi is a new therapeutic option for eligi
- 4y agoMORMPSYFNational Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell LymphomasACCESS NewswireBOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN) Clinical Practice Guidelines (NCCN Guidelines(R)) in
- 4y agoMORMPSYFInvitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022ACCESS NewswireConference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQ:MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET (8:00 pm GMT; 4:00 pm EDT). MorphoSys' Managemen
- 4y agoMORMPSYFMorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021ACCESS NewswirePublication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) announces today that it will account for a non-cash i
- 4y agoMORMPSYFMorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index ReportACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 24, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report, ranking number one in Germany and number two among Euro
- 4y agoMORMPSYFMorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial GuidanceACCESS NewswirePreliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million) Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 18, 2022 / MorphoSys AG ((
- 4y agoMORMPSYFMorphoSys To Present At the 40th Annual J.P. Morgan Healthcare ConferenceACCESS NewswirePLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG ((FSE:MOR, NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Wedn
- 4y agoMORMPSYFCorporate Calendar 2022ACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022 Dear Madam/Sir, Please note MorphoSys' financial reporting dates 2022 as follows: Publication of Interim Statement / Report Conference Call Year-End Results 2021 Mar
- 5y agoMORMPSYFMorphoSys AG Reports First Nine Months and Third Quarter 2021 ResultsACCESS NewswireMonjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-Q Ten abstracts, including two oral presentations, accepted at upcoming ASH Pelabresib data for arm 3 of MANIFEST study to be presented at ASH confirm prior data Felz
- 5y agoMORMPSYFMorphoSys Announces Departure of Roland WandelerACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management B
- 5y agoIMABMORMPSYFMorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual MeetingACCESS NewswireFelzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) present
- 5y agoMORMPSYFMorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual MeetingACCESS Newswire- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational data- MANIFEST update on pelabresib monotherapy in pa
- 5y agoMORMPSYFMorphoSys AG Announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021ACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to € 18.6 million (US$ 22 million) for the third quarte
- 5y agoMORMPSYFMorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A NephropathyACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (
- 5y agoMORMPSYFMorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's DiseaseACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for gantenerumab, an an
- 5y agoMORMPSYFMorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater ChinaACCESS NewswirePLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 17, 2021 / MorphoSys AG ((FSE:MOR, NASDAQ:MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into a collaboration and license agreement with a subsidi
- 5y agoMORMPSYFMorphoSys AG Reports Second Quarter and First Half 2021 ResultsACCESS Newswire- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q- MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals- Announced and closed ~US$ 2.0 billion strategic funding partnership
- 5y agoMORMPSYFMorphoSys AG to Update Financial Guidance for 2021 and Reduce Financial LiabilitiesACCESS NewswirePublication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2021 / MorphoSys AG ((FSE:MOR, NASDAQ:MOR) announces today an update of its financial guidance for 20
- 5y agoMORMPSYFInvitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021ACCESS NewswirePLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and fi
- 5y agoMORMPSYFRPRXMorphoSys Concludes a US $100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty PharmaACCESS NewswirePLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution to increase the share capital of MorphoSys A
- 5y agoCNSTMORMPSYFMorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-OncologyACCESS NewswireCompany Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG ((FSE:MOR, NASDAQ:MOR) ("MorphoSys") today announced the s
- 5y agoCNSTMORMPSYFMorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation PharmaceuticalsACCESS NewswireMUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), fo
- 5y agoINCYMORMPSYFMorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell LymphomaACCESS NewswireIf approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union The positive opinion from the CHMP is based on data from the Phase 2 L-MIND study evaluating
- 5y agoMORMPSYFMorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation PharmaceuticalsACCESS NewswirePLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (CNST) ("Constellation"
- 5y agoINCYMORMPSYFMorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCLACCESS NewswirePresentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR) (N
- 5y agoCNSTMORMPSYFRPRXMorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty PharmaACCESS NewswireMUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") wh
- 5y agoMORMPSYFMorphoSys To Participate in UBS Global Healthcare ConferenceACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tue
- 5y agoMORMPSYFMorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual MeetingACCESS NewswirePLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi(R)) development program will be presented at the upcoming 2021 American Society of Clinical Oncology (ASC
- 5y agoMORMPSYFMorphoSys AG Reports First Quarter 2021 ResultsACCESS NewswireMonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million) Tremfya royalties of € 11.6 million Reaffirming group revenue guidance of € 150 to € 200 million Conference call and webcast (in English) tomorrow, May 6, 2021 at 2:00pm CES
- 5y agoMORMPSYFDGAP-News: Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021ACCESS NewswireConference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibod